{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-24-000034","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.073454+00:00","generated_at":"2026-06-01T09:07:06.263629+00:00","sec_items":["7.01","9.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Supernus reports positive interim Phase 2a data for SPN-817 in treatment-resistant seizures","bullets":["75% median focal seizure reduction at 3-4 mg BID in maintenance period; 86% reduction in open-label extension.","81% of focal-seizure subjects had ≥30% reduction; 63% had ≥50% reduction in maintenance period.","Discontinuation rate due to AEs was 22% in titration and 2.4% in maintenance; common AEs: nausea, diarrhea, headache.","Company plans to initiate Phase 2b study before year-end 2024; full Phase 2a topline results expected H2 2024.","CEO states interim data provide strong evidence of clinical utility and potential differentiated treatment option."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-24-000034","json":"https://secwatch.observer/filing/0001356576-24-000034.json","markdown":"https://secwatch.observer/filing/0001356576-24-000034.md","text":"https://secwatch.observer/filing/0001356576-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000034/0001356576-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000034/supn-20240523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:07:06.263629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}